N.J. Admin. Code § 3A:56-7.5 - Psychotropic medication
(a) The home shall
not administer medication to children as a punishment, for the convenience of
staff members or as a substitute for a treatment program.
(b) The home shall ensure that a
pre-treatment clinical assessment, based on behaviors exhibited by the child
and observed by staff members, is conducted by a licensed physician before
psychotropic medication is prescribed. This pre-treatment clinical assessment
shall include at least the following information:
1. A comprehensive drug history, including
consideration of the use of all prescription and non-prescription drugs by the
child as well as a history of cardiac, liver, renal, central nervous system or
other diseases, a history of drug allergies and dietary information;
2. A laboratory work-up, including, but not
limited to:
i. A complete blood count (If the
medication prescribed requires routine follow-up blood work, this blood count
test shall be administered prior to the child's beginning his or her medication
regimen. If the medication prescribed does not require routine follow-up blood
work, a new blood count test is not required as long as the child has had a
blood count test within one year of admission, unless the physician determines
otherwise);
ii.
Urinalysis;
iii. Blood screening to
include an assessment of liver and renal functions, if indicated; and
iv. Cardiogram (EKG) and electroencephalogram
(EEG), as indicated, on children with previous histories of cardiac
abnormalities or central nervous system disorders; and
3. A written description of:
i. The purpose of the medication, the
specific behavior(s) of the child to be modified and ways in which progress
towards the treatment objectives will be measured;
ii. The dosage; and
iii. How possible side effects will be
monitored and reported to the physician who prescribed the
medication.
(c) Within two weeks after admission, the
home shall ensure that all children already receiving psychotropic medication
receive a clinical assessment by a physician, as specified in (b) above. The
home may extend this two week time period to a maximum of 30 days in which a
child receives a clinical assessment, provided that:
1. The home has the necessary amount(s) of
medication to administer to the child during any extended time
period;
2. The home has consulted
with the physician who previously prescribed the medication; and
3. The home documents the above-noted
consultation in the child's record.
(d) The home shall not be obligated to comply
with (b) above and (e) below, for a pre-treatment clinical assessment and
informed consent for psychotropic medication other than long-acting drugs if
the treating physician certifies in the child's clinical record that the child
presents a danger to self and/or others.
1.
The initial decision to administer emergency medication shall be based on a
personal examination of the child by a physician.
2. The initial administration of emergency
medication may extend for a maximum period of 72 hours.
3. A physician may authorize the
administration of medication for an additional 72 hours upon determination that
the continuance of medication on an emergency basis is clinically necessary.
This authorization may be given by telephone, provided that it is countersigned
by the physician and certified as to the necessity in the child's clinical
record within 24 hours. If this medication is then deemed necessary for the
child's treatment while in the home, the physician shall complete the
pre-treatment clinical assessment as specified in (b) above.
4. The home's staff members shall document
that the psychotropic medication was administered in an emergency situation.
The documentation shall identify possible side effects to be monitored as
described in (b)3iii above.
(e) Before administering psychotropic
medication, the home shall obtain written informed consent from the parent(s)
or legal guardian of children under the age of 18, and from all children 14
years of age and older unless the home documents that the child lacks the
capacity for informed consent. In cases where both a parent and legal guardian
exist, the home shall seek written informed consent from the legal guardian.
1. A physician, registered nurse or staff
member trained in administering psychotropic medication shall obtain written
informed consent.
2. The person
requesting written informed consent shall ensure that parents, guardians and
children are informed about:
i. The behavior
or symptoms which the medication is intended to modify;
ii. The dosage; and
iii. How possible side effects of the
medication will be treated.
3. When a request for written informed
consent is made by a non-medical staff member, the non-medical staff member
shall inform the parent or legal guardian that a physician is available for
consultation regarding the proposed medication.
4. The home may obtain verbal informed
consent by telephone from the child's parents or legal guardian when the home,
physician, registered nurse or staff member is unable to obtain written
informed consent, provided that:
i. The home
documents the telephone call in the child's record; and
ii. The home obtains the written informed
consent from the child's parents or legal guardian within 72 hours of receiving
the verbal informed consent.
5. If the home cannot obtain written informed
consent or verbal informed consent, the home shall use certified mail, return
receipt requested, and shall send the request to the parents or legal guardians
last known address at least 10 calendar days before the proposed date for the
commencement of treatment. The written notice shall specify:
i. The proposed date for beginning of
treatment; and
ii. That a failure
to respond by the proposed date for the beginning of treatment shall empower
the director, after consultation with the Divisions worker or other placing
agency to grant consent for the medication.
6. The home shall document all methods for
requesting written consent in the child's record.
(f) When a parent, legal guardian or child
refuses or revokes consent for medication, the following procedures shall
apply:
1. The treating physician or his or
her designee shall speak to the child or the parent or both to respond to the
concerns about the medication. This person shall explain the child's condition,
the reasons for prescribing the medication, the benefits and risks of taking
the medication, and the advantages and disadvantages of alternative courses of
action;
2. If the child or parent
or legal guardian continues to refuse or revokes consent to medication and the
physician or his or her designee still believes that medication is a necessary
part of the child's treatment plan:
i. The
director of the home shall invite the child and parent to attend a meeting with
the treatment team to discuss the treating physician's recommendations and the
concerns of the child or parent or legal guardian; and
ii. The treatment team shall attempt to
formulate a viable treatment plan that is acceptable to the child, parent and
legal guardian;
3. If,
after the treatment team meeting, the child or parent or legal guardian
continues to refuse or revoke consent to medication and the treating physician
still believes that medication is a necessary part of the child's treatment
plan, the home shall obtain an independent psychiatric review. The psychiatrist
conducting this independent assessment shall review the child's clinical
record, conduct a personal examination of the child, and provide a written
report for the child's treatment team; and
4. If the independent psychiatric review
supports the need for the medication and the child or parent or legal guardian
continues to refuse or revoke consent to medication, the home may initiate an
emergency discharge, as specified in
N.J.A.C.
3A:56-6.2(b) and
10.5.
(g) The home shall
administer psychotropic drugs in the following manner:
1. Psychotropic medication shall be dispensed
only by licensed pharmacists and prescriptions shall always be labeled to
reflect the following information:
i. The
name and address of the dispensing pharmacy;
ii. The full name of the
pharmacist;
iii. The full name of
the child;
iv. Instructions for
use, including the dosage and frequency;
v. The prescription file number;
vi. The dispensing date;
vii. The prescribing physician's full
name;
viii. The name and strength
of the medication;
ix. The quantity
dispensed; and
x. Any cautionary
information appropriate to the particular medication;
2. The home shall encourage the
self-administration of medication by properly trained and supervised children
whenever their intellectual, emotional, and physical capabilities make such
practice appropriate and feasible. The child's capability for
self-administration of psychotropic medication shall be documented in the
child's treatment plan; and
3. The
home shall ensure that psychotropic medication is stored as specified in
N.J.A.C.
3A:56-7.4(e).
(h) The home shall ensure that all
children receiving psychotropic medication are monitored in the following
manner:
1. Staff members directly involved
with the child shall record:
i. At least
weekly progress towards treatment objectives; and
ii. Daily observed side effects which are
identified in the pre-treatment clinical assessment;
2. Staff members shall notify the prescribing
physician immediately, when side effects are observed;
3. The home shall ensure that:
i. The physician or his or her designee
reviews every 30 days the child's status, behavior, well-being and progress
towards treatment objectives, side effects and reason for continuing the
medication;
ii. The review is
documented in the child's medical record; and
iii. The home informs the child, parents,
legal guardian, the Divisions worker, or other placing agency about the outcome
of the review.
(i) The home shall ensure that any staff
member involved in administering psychotropic medication receive the following
training:
1. Indications for drug use;
and
2. Therapeutic and side
effects.
(j) The home
shall record all information about a child's psychotropic medication, as
specified in
N.J.A.C.
3A:56-7.4(d), and the home
shall ensure that the child's medication record is available to the physician
for review when additional medication is prescribed.
(k) Where the term "physician" is referenced
in this section, an advanced practice nurse (APN) may provide the indicated
service, as licensed and supported by a collaborative agreement with a
psychiatrist and joint protocol document as specified in
N.J.A.C.
13:37-8.1.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.